Last month, infectious disease experts gathered in Melbourne, Australia, to decide on which influenza virus strains to include in the seasonal flu vaccine for the Southern hemisphere's flu season. Such gatherings, organized by the World Health Organization (WHO), are held twice a year. But this meeting was unusual because discussion of the seasonal flu vaccine was overshadowed by discussion of vaccine production to combat the new H1N1 pandemic swine flu strain.
In mid to late March this year, a new influenza A virus (subtype H1N1) of swine origin emerged in Mexico and the United States, quickly spreading to more than 30 countries by mid-May. In mid-June, the WHO declared the first flu pandemic in four decades, and the race was on to produce sufficient vaccine against the H1N1 virus by October 2009, the start of the Northern hemisphere flu season. In a world far removed from that of the father of vaccination, Edward Jenner, the collective effort of scientists worldwide has done just that. "The vaccine groups have done magnificently," says virologist John Oxford at Queen Mary School of Medicine in London. "Over 30,000 people have devoted the last 40 years to developing these vaccines and their efforts have come to fruition in the production of the swine flu vaccine."
Most of the swine flu vaccines currently available were produced by the standard method of culturing the virus in chicken eggs. The vaccine is then made from the whole killed virus, or by treating the virus with ether or detergent to produce a subunit vaccine. For example, the Novartis swine flu vaccine, Focetria, is a subunit vaccine produced in eggs and contains the hemagglutinin (HA) and neuraminidase (NA) surface antigens of the H1N1 influenza virus. But influenza viruses that thrive in humans are hard to grow in chicken eggs, and the eggs are expensive and in short supply. So different labs worldwide are finding new ways to boost the yield of virus from eggs and are developing innovative methods to avoid the use of eggs altogether by culturing the virus in cell lines. About 10% of currently available swine flu vaccines have been made using new methods. For example, MedImmune's vaccine is a live attenuated virus produced by engineering a cold adapted influenza virus (that doesn't replicate at human body temperature) to express genes encoding the hemagglutinin and neuraminidase of the H1N1 virus. Baxter's vaccine is produced by culturing the virus in a Vero cell line, rather than in eggs. Novartis is also developing a swine flu vaccine using virus cultured in an MDCK cell line.
Increasing the Yield
A key way to increase virus yield from eggs is the classical reassortment method. In this method, the new influenza virus is injected into the allantoic cavity of a 10-to 12-day-old fertilized chick egg along with an influenza virus known to grow well in eggs, usually A/ PR/8/34 (known as PR8) for influenza A virus strains. The hope is that the eight genes in each of the two viruses will reassort resulting in a virus that contains six genes for rapid growth from the PR8 strain and the two genes encoding the hemagglutinin and neuraminidase surface antigens from the new virus.
"After the first 42 hour incubation period there are potentially 256 combinations of genes amongst the resulting reassortants," says Doris Bucher of New York Medical School. To narrow these down and promote "positive selection for growth and negative selection for [PR8] surface antigens, the reassortants undergo subsequent incubation cycles where antibodies to PR8 surface antigens, HA and NA, are added." By the end of this process, reassortants expressing antigens from PR8 should have been removed, leaving only reassortants with the surface antigens of the new virus. Lastly, these desired reassortants are cloned and amplified.
"Reverse genetics is the other way of producing a rapidly growing strain with the required antigens," says Robert Webster, an influenza expert at St. Jude's Children's Research Hospital in Memphis, Tennessee. This method was brought into play a couple of years ago when trying to culture the avian influenza virus H5N1, the emergence of which had sparked fears of a possible pandemic. "It just wouldn't grow using any of the other methods," he notes.
Vaccine Production from A to Z Producing a vaccine to a new strain of influenza virus follows a standard process. At the first report of any outbreak, the WHO's Global Influenza Surveillance Network starts working to identify the culprit virus (http://www.who.int/csr/ disease/influenza/surveillance/en/index. html). This network continually monitors changes in circulating viruses. Identification of a local virus type and subtype is carried out at national influenza centers and samples requiring further analysis are sent on to a collaborating center. "The global flu network was established 60 years ago with the original influenza center in London," says Alan Hay, director of the London collaborating center. This center is one of five, with others in Tokyo, Melbourne, Memphis, and Atlanta. "The collaborating centers define antigenic drift both subjectively, by testing the virus against ferret antiserum to previous viruses, and objectively, by sequencing the viral genome. These two methods combine to give very reliable data," says Hay. Using these techniques the US Center for Disease Control and Prevention (CDC) in Atlanta, Georgia (http://www.cdc.gov/flu/) identified the
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new H1N1 swine flu virus by the end of April this year, just 6 weeks after the first cases were reported.
Then "the race was on between the collaborating centers and other, mainly academic, laboratories to culture the strain which grew the quickest for use in a vaccine," says Webster. Influenza viruses are quasispecies with many slightly different variants and "at the end of the culture process it is hoped that you can fish out a rapidly growing virus that contains the antigens you are interested in for the companies to use as their seed strain for vaccine manufacture," he says. Each lab chooses their own method to culture a rapid growth strain, but as Webster points out "there is a huge amount of collaboration between the laboratories at this stage, involving a lot of talking and swapping notes."
It was Doris Bucher's group, using the classical reassortment method, that produced the virus that was selected as the seed strain to produce vaccines against H1N1. Bucher explains, "We played a trick when we made H1N1, and dressed it up in H3N2's clothing. Instead of mixing the wildtype virus identified by CDC with PR8, we used one of our favorite reassortants, NYMC X-157." This reassortant has the desired six genes for rapid growth from PR8, with the hemagglutinin and neuraminidase coming from an old H3N2 New York strain. To ensure that reassortants in the seed strain only contained swine influenza virus surface antigens, Bucher added antibodies directed against the surface antigens of X-157 during the culture process.
A number of candidate H1N1 seed strains were made by other labs using reverse genetics, but these did not grow as well as Bucher's strain. "This may be because the classic reassortment method allows for a 'swarm of variants' so there is a greater chance that one in this swarm will grow well. The reverse genetics method is more targeted, so there might be less variation," explains Bucher.
The candidate seed strains made by different labs are sent to one of the five collaborating centers, which test that the seed strains produce robust immune responses using ferret antiserum to the wild-type virus. Among the strains that produce a good response, the strain that grows the quickest is selected as the seed strain, which is then made available to pharmaceutical companies for the mass manufacture of vaccine.
"The 2009 H1N1 influenza virus is a new virus, but the process for making vaccine is the same as for seasonal strains," says Anthony Fauci, Director of the US National Institute of Allergy and Infectious Diseases, part of the US Department of Health and Human Services (DHHS) (http://www3.niaid.nih.gov/ topics/Flu). "The HHS provides funds and resources to allow production of seasonal flu vaccines on a yearly basis and the companies collaborate as part of an agreement to provide resources when required to rapidly produce a vaccine for a pandemic," he says.
From Academia to Pharma
Once the chosen seed strain reaches pharmaceutical companies, the scientists at big pharma continue to select rapidly growing strains. "Although pharmaceutical companies are working hard to provide a vaccination beneficial to human health, they are also trying to make a profit," says Webster. Webster adds, "there has never been a reason to force companies to collaborate and share information, as the seed stock from the academic labs is always very good. With swine flu, once Doris Bucher had done her work, the growth of the virus was about as good as it gets."
Once companies have successfully cultured their seed virus, they treat it to make an inactivated whole virus or a subunit vaccine. Adjuvants can be added to increase the immunogenicity of the vaccine, with the advantage of less vaccine being needed to produce the same antibody response. This is of huge benefit when dealing with a pandemic when vaccine may be in short supply. Two of the three swine flu vaccines approved in Europe contain adjuvant, but currently none of the US vaccines do. The US has adjuvants for use in an emergency, but due to the good immunogenicity of the swine flu vaccines, adjuvants may not be needed.
From identifying the swine influenza virus in April to regulatory approval for the vaccines took only 6 months. Currently, four H1N1 vaccines-from CSL Ltd., MedImmune LLC, Novartis, and Sanofi 
A Lack of Innovation
It seems that this system has worked seamlessly, but there are concerns that it could have been better. Ninety percent of the currently available swine flu vaccines were made using chicken eggs, with only 10% using newer, quicker methods (that is, MedImmune's live attenuated vaccine, and the vaccines produced in cell culture by Baxter and Novartis).
"There are many advantages of a cell culture system," says Noel Barrett, Vice-President R&D Vaccines at Baxter Innovations. "It obviates the need for the hundreds of millions of fertilized eggs per year. It is also more likely to be sterile than production in eggs." In addition "the cells can be stored in the freezer and brought into production whenever they are needed." Using cell culture also circumvents the time-consuming need to genetically modify virus to grow in eggs. For their swine flu vaccine, Baxter simply grew the wild-type virus in their Vero cell line, which meant that they did not have to wait for the academic labs to grow a seed strain. But despite these advantages, getting this method off the ground required considerable investment. "The cost of building new facilities is high and has to be written off over a period of approximately 20 years, which obviously reduces profit margins," says Barrett, "and there is the high cost of conducting clinical trials to get the novel vaccines licensed." "The need to make a profit and the high costs of developing new vaccines means that innovations often come from academics rather than companies," says Mike Skinner, head of the Vaccine Vector Group at Imperial College in London. "In general companies look at the bigger, easier targets," he says "but that is not what drives new vaccine development.
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When the targets are harder, academic labs can afford to look at radical new methods that may work and the 'maybe this will work' approach drives vaccine development forward."
Webster notes that the diminished interest of big pharma in flu vaccines has been "problematic in the past." "The lack of financial incentives has meant that most companies stopped producing flu vaccines in the US, this means the US has to source most of its vaccines offshore," says Webster. In the 2004-2005 regular flu season, for example, there was only one company in the US producing vaccine. However, as concerns about a possible avian flu pandemic increased, the US government boosted its investment in flu vaccine production. Webster notes, "We are still currently dependent on offshore vaccine production with the consequence that if the swine flu virus had started killing people in those [offshore] countries their commitment to provide vaccine to the US could have been overruled."
Addressing the Problem
The US DHHS started to address the lack of innovation in flu vaccine production through its BARDA unit (Biomedical Advanced Research and Development Authority; http://www.hhs.gov/aspr/barda). Launched in 2000, BARDA coordinates the development, production, and purchase of the necessary vaccines, drugs, and diagnostics to combat public health emergencies. Recently, BARDA has ramped up its efforts to boost flu vaccine production and to foster development of flu vaccines using new methods.
BARDA has pumped more than $5.5 billion into influenza vaccine development and production over the last 4 years. For example, in 2007 alone, $120 million was given to onshore companies to increase production of egg-based flu vaccines in the US. But concerns that the egg-based method is too unreliable and sluggish to be ideal for pandemic situations prompted an extra injection of funds to stimulate companies to speed innovations in flu vaccine development.
Michael Perdue, director of the Division of Influenza and Emerging Diseases at BARDA, says companies receiving such funds include GSK, which is developing a new avian cell line in which to grow avian influenza virus. "The idea is that it would produce very high levels of an avian origin virus compared to mammalian cell lines," says Perdue. "We are funding Novartis, GSK and Intercell for development of adjuvants," he adds. In January this year, Novartis received nearly $500 million from BARDA to develop an MDCK cell culture method for flu vaccine production in the US. But the funds are not limited to US companies: Baxter, which is based in Vienna, Austria, also received BARDA funds to help in the process of gaining FDA approval for its vaccine produced in cultured cells.
Another company to benefit from DHHS's innovation funding is Protein Sciences in Connecticut, whose subunit seasonal flu vaccine consists of pure hemagglutinin produced in a baculovirus expression vector system. Manon Cox, the Chief Operating Officer at Protein Sciences, welcomes the new funds but cautions that "The support is going to the old as well as the new technologies, which means that larger companies have no incentive to explore new technologies if they are getting money for continuing with the old one." However, she realizes that there is no easy solution: "You can't throw away your old shoes before you buy a new pair," she says.
From Pharma to the Clinic Pilot (investigational) lots of the different H1N1 flu vaccines developed by pharmaceutical companies are sent back to academic and government labs for clinical trials where they are tested for safety and efficacy. As the swine flu vaccines are produced using methods already tested with seasonal flu vaccines, they are unlikely to produce unforeseen safety issues. However, they have been thoroughly tested on thousands of people prior to approval. "One of the reasons for such rigorous testing may be to reassure the public that the vaccine is indeed safe," says virologist John Oxford.
The results of the first clinical trials of the subunit swine flu vaccines were published in the New England Journal of Medicine in early September (http:// content.nejm.org /cgi /content /full / NEJMe0908224). These studies showed that the vaccines could be effective even if used sparingly; just a single dose was immunogenic, although a two-dose regime produced greater antibody titers. In addition, the subunit vaccine containing adjuvant was immunogenic at half the dose of the subunit vaccine without adjuvant. So far, says Fauci, studies have shown that the vaccine is well tolerated with little in the way of safety issues. In addition, even though the vaccines have been produced by several different companies the responses to them in trials have been equitable. Just 6 months after the H1N1 swine flu virus was identified, vaccines have been approved for use in the US, many European countries, as well as Australia, China, and Japan. Other countries will soon follow suit. From analyzing figures on production since May 2009, the WHO estimates that 3 billion doses of flu vaccine can now be produced per year in a pandemic. With flu season starting, the scientists' job may be done, but the race to vaccinate as many people as possible against swine flu and seasonal flu has just begun for public health officials around the globe.
